Boehringer Ingelheim GmbH, of Ingelheim, Germany, said it initiated a study of idarucizumab as an antidote for rapid reversal of Pradaxa (dabigatran etexilate)-induced anticoagulation. Emergency rooms in more than 35 countries worldwide will participate in this study, with physicians using idarucizumab as a ready-to-use solution for infusion. The study was initiated at sites in Europe, with additional sites and countries expected to follow throughout the year.